Introduction {#acn3396-sec-0001}
============

Paraneoplastic neurological syndromes (PNS) include a variety of immune‐mediated neurological disorders that occur in association with cancer. PNS is caused by an immune reaction directed at an autoantigen that is shared by neurons and cancer cells. Mostly, the neurological symptoms precede the diagnosis of cancer. Early recognition of PNS can facilitate tumor detection and treatment and thereby increases the chance of stabilizing the neurological symptoms.[1](#acn3396-bib-0001){ref-type="ref"}

The immune reaction in PNS is often hallmarked by the presence of antineuronal antibodies in patient serum or cerebrospinal fluid (CSF). The detection of antineuronal antibodies has proven to be a useful tool in PNS diagnosis. Some antineuronal antibodies, such as anti‐DNER (Tr), are very syndrome and tumor specific.[2](#acn3396-bib-0002){ref-type="ref"}, [3](#acn3396-bib-0003){ref-type="ref"} Others, such as anti‐Hu, are associated with a variety of neurological syndromes but predict an underlying small‐cell lung carcinoma (SCLC) in most cases.[4](#acn3396-bib-0004){ref-type="ref"}

Autoantibodies to components of the axon initial segment (AIS) and (para)nodes of Ranvier (NOR) have been reported in PNS and other neurological disorders.[5](#acn3396-bib-0005){ref-type="ref"}, [6](#acn3396-bib-0006){ref-type="ref"}, [7](#acn3396-bib-0007){ref-type="ref"}, [8](#acn3396-bib-0008){ref-type="ref"} The AIS and NOR are molecularly related axonal regions that are involved in the initiation and propagation of action potentials.[9](#acn3396-bib-0009){ref-type="ref"} Recently, the protein tripartite motif 46 (TRIM46) was found to be the autoantigen in a patient with paraneoplastic encephalomyelitis (PEM) and antibodies to the AIS but not the NOR of the sciatic nerve.[6](#acn3396-bib-0006){ref-type="ref"}, [10](#acn3396-bib-0010){ref-type="ref"} TRIM46 localizes specifically to the proximal axon where it bundles parallel microtubules and is important for axon specification and outgrowth during early brain development.[10](#acn3396-bib-0010){ref-type="ref"}

Here, we clinically and experimentally characterize three patients with antibodies to TRIM46. We show that TRIM46 antibodies are associated with the presence of a SCLC and can present with a broad clinical variety of central nervous system (CNS) symptoms.

Materials and Methods {#acn3396-sec-0002}
=====================

Patients with AIS staining were identified in two European PNS laboratories (Erasmus University Medical Center (EMC), Rotterdam, the Netherlands. IDIBAPS, Barcelona, Spain) that test over 2000 samples yearly for the presence of onconeuronal antibodies. Routine diagnostic testing was performed using immunohistochemistry (IHC) of rat brain slices. The AIS staining patterns of patient 1 and 2 were previously described.[6](#acn3396-bib-0006){ref-type="ref"}, [11](#acn3396-bib-0011){ref-type="ref"} This study was approved by the Institutional Review Board of the EMC.

The controls included serum or plasma from 88 anonymous blood bank donors, 20 reumatoid factor‐positive patients, 10 patients with systemic lupus erythematosus, 10 patients with Sjögren\'s syndrome, 30 patients with anti‐Hu antibodies and SCLC and 50 patients with SCLC without neurological symptoms (13 with limited disease, 31 with extensive disease, six with unknown disease severity) that were previously used in Ref. 12

The following antibodies and reagents were used in this study: mouse anti‐ankyrinG (Life Technologies, Carlsbad, USA), chicken anti‐MAP2 (Abcam, Cambridge, UK), mouse anti‐GFP (Roche, Almere, Netherlands), rabbit anti‐TRIM46 (in‐house, generated as described in[10](#acn3396-bib-0010){ref-type="ref"}), and Alexa‐405, ‐488, or ‐568‐conjugated secondary antibodies directed at human, mouse, chicken, or rabbit IgG (Thermo Fisher, Landsmeer, Netherlands). For western blotting, horseradish peroxidase‐conjugated donkey anti‐human (Calbiochem, Amsterdam, Netherlands) and swine anti‐mouse (DAKO, Heverlee, Belgium) were used. For immunohistochemistry, biotin‐conjugated goat anti‐human IgG antibodies (Vector Laboratories, Youngstown, USA) and Vectastain Elite ABC complex (Vector Laboratories, Youngstown, USA) were used.

The TRIM46 and TRIM36 DNA clones were kindly provided by Dr. T Cox.[13](#acn3396-bib-0013){ref-type="ref"} Expression constructs and chimeric constructs were generated in‐house by PCR as described in Ref. 10. Primer sequences are available on request. Immunohistochemistry of rat brain slices and SCLC tissue with diaminobenzidine stain was performed essentially as described in Ref. 14. Fluorescent staining of brains from P5 C57BL/6 wild‐type mice was performed as described in Ref.10. Primary hippocampal neuron cultures were obtained according to established procedures.[15](#acn3396-bib-0015){ref-type="ref"} DNA transfection and immunofluorescent staining procedures of HeLa cells and neurons and western blotting were performed as described in Ref.14. Confocal images were acquired with the Zeiss LSM 700 using the 63× oil objective.

Results {#acn3396-sec-0003}
=======

Routine IHC screening for onconeuronal antibodies revealed serum samples from three patients with staining of the AIS throughout the rat brain (Fig. [1](#acn3396-fig-0001){ref-type="fig"}A). Detailed clinical information on these patients can be found in Table [1](#acn3396-tbl-0001){ref-type="table-wrap"}. Patient 1 presented with PEM and SCLC. Patient 2 presented with cerebellar degeneration and was diagnosed with SCLC 10 months later. Patient 3 presented with rapidly progressive dementia, resembling Creuzfeldt‐Jakob disease, without a known underlying tumor. No other antineuronal antibodies were detected. Patient 1 showed no response to oncologic treatment and died of tumor progression 3 months after onset of the neurological symptoms. Patient 2 was lost to follow up and patient 3 died of neurological progression 7 months after onset of the neurological symptoms. At autopsy of the brain from patient 3 showed extensive perivascular and parenchymal CD8^+^ T‐cell infiltration.

![Identification and validation of TRIM46 as neuronal autoantigen. (A) Immunohistochemistry (IHC) of adult rat brains stained with the patients' serum. The figures depict a part of the cortex showing prominent staining of the axon initial segment (AIS) (indicated with arrows) by the patients' sera, which is absent in the staining with healthy control serum. Scale bars: 50 *μ*m (B) IHC of P5 mouse cortex. The patients' sera (green) stain the initial part of the axon and partially colocalize with the AIS marker ankyrinG (red). Scale bars: 20 *μ*m. (C) Immunocytochemistry of cultured rat hippocampal neurons (DIV25). The patients' sera (red) stain the initial part of the axon and partially colocalize with the AIS marker ankyrinG (green) but not with the dendritic marker MAP2 (blue). Scale bars: 20 *μ*m. (D) HeLa cells expressing TRIM46‐GFP (green) were fixed, permeabilized and stained with patients' or healthy control sera (red). The patients' sera strongly recognize TRIM46, whereas the control serum does not. Scale bars: 10 *μ*m. (E) Western blots using lysates of HEK cells overexpressing GFP or TRIM46‐GFP. The blots were stained with a GFP antibody, TRIM46 antibody, patients' or healthy control sera. The patients' sera recognize TRIM46‐GFP on blot but not GFP. (F) IHC of tumor tissue from patient 1, stained with hematoxylin‐eosin (HE), the lung carcinoma marker thyroid transcription factor 1 (TTF‐1), normal rabbit serum, and TRIM46 antibody. The picture shows TRIM46 expression in a subset of tumor cells. Stainings were performed on sequential slides, pictures were taken in the same area of the sample. Scale bars: 25 *μ*m.](ACN3-4-680-g001){#acn3396-fig-0001}

###### 

Patients' clinical information

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               Patient 1                                                                                                                                                                                                                                  Patient 2                                                                                                                                 Patient 3
  -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Gender                                       Male                                                                                                                                                                                                                                       Male                                                                                                                                      Female

  Age at disease onset                         78 years                                                                                                                                                                                                                                   64 years                                                                                                                                  73 years

  Neurological syndrome                        Progressive encephalomyelitis                                                                                                                                                                                                              Cerebellar ataxia                                                                                                                         Rapidly progressive dementia

  Main symptoms                                Gait instability, change of character, complex partial seizures                                                                                                                                                                            Vertigo, nausea, vomiting, truncal ataxia                                                                                                 Mood disorder, rapidly progressive dementia, followed by ataxia, myoclonus, dysarthria, sleep cycle inversion

  Tumor                                        SCLC                                                                                                                                                                                                                                       SCLC                                                                                                                                      No tumor on thoraco‐abdominal CT‐scan

  Brain CT/MRI                                 Normal                                                                                                                                                                                                                                     Normal                                                                                                                                    Bilateral hyperintensity (T2, DWI) in the head of the caudate and pallidum, right hippocampus and right anterior cingular gyrus

  EEG                                          Not performed                                                                                                                                                                                                                              Not performed                                                                                                                             Progressive diffuse slowing

  Blood examination                            Na 120 mmol/l (SIADH)                                                                                                                                                                                                                      Normal                                                                                                                                    Normal

  CSF examination                              1 WBC/*μ*L. Normal protein, glucose, and cytology.                                                                                                                                                                                         25 WBC/*μ*L. Normal protein, glucose, and cytology                                                                                        14 WBC/*μ*L. Protein: 0.723 g/L. Normal glucose and cytology. 14‐3‐3 positive

  Paraneoplastic/Neuronal surface antibodies   Negative (Hu, Yo, Ri, Amp)                                                                                                                                                                                                                 Negative (Hu, Yo, Ri, Ma1, Ma2, Tr, Amp, NMDAR, AMPAR, GABAbR, GABAaR, LGI1, CASPR2, DPPX, GlycineR, Zic4, Sox1, CRMP5, GAD65, VGCC)      Negative (Hu, Yo, Ri, Ma1, Ma2, Tr, Amp, NMDAR, AMPAR, GABAbR, GABAaR, LGI1, CASPR2, DPPX, GlycineR, VGKC, Zic4, Sox1, CRMP5, GAD65)

  Treatment                                    Etoposide (1 cycle)                                                                                                                                                                                                                        Unknown                                                                                                                                   No

  Neurological response\                       No                                                                                                                                                                                                                                         Unknown                                                                                                                                   N.A.
  to treatment                                                                                                                                                                                                                                                                                                                                                                                                                      

  Brain autopsy                                Not performed                                                                                                                                                                                                                              Not performed                                                                                                                             Perivascular and parenchymal CD8^+^ infiltration. Most prominent in limbic regions. Extensive neuronal loss. No evidence for CJD

  Disease course                               Change of character, gait instability and complex partial seizures developed over weeks. Diagnosis of SCLC (extensive disease). After one cycle of etoposide, the tumor progressed and the patient died 3 months after onset of symptoms   Subacute cerebellar and brainstem symptoms. Diagnosis of SCLC was made 10 months after onset of symptoms. Patient was lost to follow up   Rapidly progressive dementia mimicking CJD. No tumor was found. Patient died of neurological progression 7 months after onset of symptoms
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCLC, small‐cell lung carcinoma; CJD, Creuzfeldt‐Jakob disease; SIADH, syndrome of inappropriate ADH secretion. WBC, white blood cells.
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To verify the specific labeling of the proximal axon, we performed double immune labeling using the patients' sera and the well‐known AIS marker ankyrinG (AnkG). The staining pattern of the patients' sera largely colocalized with AnkG both in mouse brain (Fig. [1](#acn3396-fig-0001){ref-type="fig"}B) and cultured rat hippocampal neurons (Fig. [1](#acn3396-fig-0001){ref-type="fig"}C).

To identify the molecular target of the antibodies, we tested the reactivity of the patients' sera against various AIS proteins. The patients' antibodies did not react with *β*IV‐spectrin and AnkG (data not shown). Also, the patient sera did not label the surface of live hippocampal neurons, as would be expected for antibodies against neurofascin‐186 (NF186). All three sera specifically reacted with TRIM46 in a cell‐based assay (CBA) (Fig. [1](#acn3396-fig-0001){ref-type="fig"}D) and on western blot (Fig. [1](#acn3396-fig-0001){ref-type="fig"}E). We tested 208 healthy and disease controls of which none reacted with TRIM46 in a CBA (Fig. [1](#acn3396-fig-0001){ref-type="fig"}D, data not shown).

To test whether the immune reaction could have been triggered by aberrant expression of TRIM46 by the SCLC, we performed IHC on the SCLC tissue of patient 1. The patient\'s tumor tissue showed specific TRIM46 expression (Fig. [1](#acn3396-fig-0001){ref-type="fig"}F).

Next, we mapped the epitopes of the patients' antibodies using chimeric constructs of GFP‐TRIM46 and ‐TRIM36. TRIM36 is a family member that is highly similar to TRIM46[13](#acn3396-bib-0013){ref-type="ref"} but does not localize to axonal microtubules and is not recognized by the patients' antibodies. By swapping domains of TRIM46 with the corresponding regions of TRIM36, we were able to identify the specific domains to which the anti‐TRIM46 antibodies are directed. All three patients had multiple epitopes on the B‐box, coiled‐coil, and C‐terminal domains of TRIM46 (Fig. [2](#acn3396-fig-0002){ref-type="fig"}).

![Epitope mapping of anti‐TRIM46 autoantibodies. Schematic representation of TRIM46 (gray) and TRIM36 (white). **CC** = coiled‐coil. **COS** = C‐terminal subgroup one signature. **FN** **3** = Fibronectin type III. GFP‐tagged truncated TRIM46 and chimeric proteins of TRIM46 and TRIM36 (green) expressed in HeLa cells and stained with patient\'s serum (red). The patients' sera recognize the TRIM46 C‐terminus and N‐terminal B‐box, and CC region.](ACN3-4-680-g002){#acn3396-fig-0002}

Conclusion and Discussion {#acn3396-sec-0004}
=========================

In this article, we describe a novel onconeuronal antibody directed at the AIS protein TRIM46. We clinically and experimentally characterize three patients with anti‐TRIM46 antibodies and show that these antibodies are associated with CNS symptoms and an underlying SCLC. Anti‐TRIM46 antibodies are polyclonal and directed at multiple, most likely linear epitopes on TRIM46. Anti‐TRIM46 antibodies can robustly be detected with multiple techniques.

Although the number of patients in this case series is too small to make any general conclusions, the patients' diverse symptoms fit with the expression of TRIM46 throughout the CNS. A large variety in clinical presentation is also seen in disorders associated with other onconeuronal antibodies such as anti‐Hu.[4](#acn3396-bib-0004){ref-type="ref"} Similar to anti‐Hu, anti‐TRIM46 antibodies are associated with an underlying SCLC. However, although low titers of anti‐Hu antibodies occur in 16--26% of patients with SCLC without PNS,[12](#acn3396-bib-0012){ref-type="ref"}, [16](#acn3396-bib-0016){ref-type="ref"}, [17](#acn3396-bib-0017){ref-type="ref"} we did not detect anti‐TRIM46 antibodies in sera from patients with SCLC but without neurological symptoms.

TRIM46 antibodies are polyclonal and directed at immunoreactive epitopes in the B‐box, coiled‐coil, and C‐terminal domains of TRIM46. A polyclonal immune reaction, directed at multiple immunogenic sites that are shared between individual patients, is similar to the well‐studied onconeuronal antigen HuD.[18](#acn3396-bib-0018){ref-type="ref"}, [19](#acn3396-bib-0019){ref-type="ref"} As TRIM46 is a cytosolic protein, most likely not a humoral but a T‐cell‐mediated response against TRIM46 is causing the neurological dysfunction. The autopsied brain of patient 3 indeed showed infiltration with CD8^+^ T cells. Also the poor prognosis of all three patients is in line with irreversible neuronal damage. The presence of TRIM46 in the SCLC of one of the patients suggests that ectopic TRIM46 expression by tumor tissue is the immunological trigger. However, as an underlying SCLC was not found in one of the patients, a possible nonparaneoplastic nature of anti‐TRIM46 antibodies cannot be ruled out.

We have only rarely detected staining of the AIS in routine IHC. In all cases known to us, this was due to antibodies to TRIM46 and could robustly be confirmed with multiple laboratory techniques. Autoantibodies to other components of the AIS have been reported in literature; for example, antibodies to NF186 have been detected by ELISA in a small group of patients with peripheral neuropathies. Their frequency of occurrence varies greatly between different studies and their clinical value remains unclear.[8](#acn3396-bib-0008){ref-type="ref"} Antibodies to scaffold protein AnkG are present in patients with Alzheimer\'s disease and in up to 25% of healthy individuals over 65 years of age.[7](#acn3396-bib-0007){ref-type="ref"} The discrepancy between the reported high frequency of AnkG antibodies and the low frequency of AIS staining on IHC could be explained by detection methods used (only western blot for AnkG antibodies). Possibly, the formation of AnkG antibodies is triggered by neurodegeneration occurring with age and should be seen separate from the highly specific antibodies occurring in PNS, such as anti‐TRIM46 antibodies.

In this case series, we show that anti‐TRIM46 antibodies are rare but easy to detect in routine IHC for intracellular antigens. They can occur in patients with diverse neurological syndromes, and can be associated with SCLC.
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